Call the shots: vaccine cuts imperil global health

Call the shots: vaccine cuts imperil global h...

Up next

An explosion still echoing: Chernobyl at 40

We go deep inside the Chernobyl nuclear-power plant and the surrounding exclusion zone, recounting the history of the accident on April 26 1986, and speaking with plant workers who were on shift that day. A pre-eminent Chernobyl historian discusses the lessons learned and yet to ...  Show more

Bringing the House down: our American midterms model

We examine what our forecast model predicts so far—and consider what might change its confident prediction for one house of Congress and toss-up call for the other. Our correspondent sits down with Steve Reich, a pioneering classical composer who is nearing his 90th birthday. And ...  Show more

Recommended Episodes

Call the shots: vaccine cuts imperil global health
The Intelligence from The Economist

America’s health secretary, RFK Jr, is known for his opposition to vaccines, particularly mRNA jabs, that have the potential to treat a large swathe of diseases. Slashing funding will have long term implications beyond America. Our correspondent visits Britain’s biggest and newes ...  Show more

The human strain: can mpox be contained?
The Intelligence from The Economist

Mpox is spreading fast across Africa, yet public information campaigns are scant and vaccines in short supply. Is a new pandemic in the offing? Strategists are pondering a new potential threat from Russia: the possibility that it could detonate a <a href="https://www.economist ...

  Show more

Rio brand: why Brazil is courting China
The Intelligence from The Economist

Trade ties between <a href="https://www.economist.com/the-americas/2024/11/17/brazil-courts-china-as-its-musk-feud-erupts-again?utm_campaign=a.io&utm_medium=audio.podcast.np&utm_source=theintelligence&utm_content=discovery.content.anonymous.tr_shownotes_na-na_article&utm_term= ...

  Show more

Wary pharma: AstraZeneca sours on UK
The Intelligence from The Economist

Pharmaceutical giant AstraZeneca has paused a £200m investment in Britain and could move its primary listing to America. Can the UK maintain its status as a “life-science superpower”? Why autonomous air wings are the future of war in the sky. And how scientists in the Caribbean a ...  Show more